A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 201M | 201M | 200M | 193M | 164M | 128M |
| Net Income | -67M | -67M | -6.0M | -12M | 2.6M | 3.0M |
| EPS | $-0.52 | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.02 |
| Free Cash Flow | -8.8M | -8.8M | 22M | 633K | -22M | 266K |
| ROIC | -11.9% | -18.0% | -1.5% | -3.0% | 0.6% | 2.8% |
| Gross Margin | 51.8% | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% |
| Debt/Equity | 0.05 | 0.05 | 0.03 | 0.03 | 0.05 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -40M | -40M | -21M | -28M | -1.8M | 9.2M |
| Operating Margin | -20.0% | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% |
| ROE | -19.5% | -18.0% | -1.5% | -3.0% | 0.6% | 1.6% |
| Shares Outstanding | 128M | 128M | 120M | 135M | 129M | 134M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | 128M | 164M | 193M | 200M | 201M | 201M |
| Gross Margin | N/A | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% | 51.8% |
| R&D | 14M | 24M | 35M | 44M | 39M | 36M | 36M |
| SG&A | 9.4M | 21M | 35M | 44M | 43M | 59M | 59M |
| EBIT | 14M | 9.2M | -1.8M | -28M | -21M | -40M | -40M |
| Op. Margin | N/A | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% | -20.0% |
| Net Income | 3.2M | 3.0M | 2.6M | -12M | -6.0M | -67M | -67M |
| Net Margin | N/A | 2.4% | 1.6% | -6.3% | -3.0% | -33.0% | -33.0% |
| Non-Recurring | 1.6M | 488K | 756K | 1.5M | 1.6M | 1.3M | 1.3M |
| Returns on Capital | |||||||
| ROIC | 106.4% | 2.8% | 0.6% | -3.0% | -1.5% | -18.0% | -11.9% |
| ROE | 25.1% | 1.6% | 0.6% | -3.0% | -1.5% | -18.0% | -19.5% |
| ROA | 1.5% | 0.9% | 0.5% | -2.4% | -1.2% | -13.8% | -14.4% |
| Cash Flow | |||||||
| Op. Cash Flow | 15M | 4.6M | -12M | 5.3M | 25M | -4.7M | -4.7M |
| Free Cash Flow | 14M | 266K | -22M | 633K | 22M | -8.8M | -8.8M |
| Owner Earnings | 14M | -3.2M | -31M | -23M | -8.7M | -37M | -37M |
| CapEx | 1.5M | 4.4M | 9.7M | 4.6M | 3.5M | 4.1M | 4.1M |
| Maint. CapEx | 603K | 1.2M | 2.5M | 6.0M | 7.2M | 7.6M | 7.6M |
| Growth CapEx | 944K | 3.1M | 7.3M | 0 | 0 | 0 | 0 |
| D&A | 603K | 1.2M | 2.5M | 6.0M | 7.2M | 7.6M | 7.6M |
| CapEx/OCF | N/A | 94.3% | N/A | 88.0% | 13.9% | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 44M | 22M | 81M | 81M |
| Buyback Yield | N/A | N/A | N/A | 3.5% | 2.8% | 2.3% | 13.8% |
| Stock-Based Comp | 611K | 6.6M | 17M | 22M | 27M | 25M | 25M |
| Debt Repayment | 0 | 0 | 50K | 565K | 557K | 4.7M | 4.7M |
| Balance Sheet | |||||||
| Net Debt | N/A | -710M | -320M | -249M | -266M | -244M | -73M |
| Cash & Equiv. | 165M | 365M | 297M | 167M | 99M | 91M | 91M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 17M |
| Debt/Equity | -2.60 | 0.00 | 0.05 | 0.03 | 0.03 | 0.05 | 0.05 |
| Interest Coverage | 41.0 | 5.3 | -0.7 | -13.4 | -3.9 | -85.2 | -85.2 |
| Equity | -16M | 405M | 426M | 393M | 396M | 342M | 342M |
| Total Assets | 220M | 463M | 519M | 494M | 500M | 462M | 462M |
| Total Liabilities | 42M | 58M | 94M | 101M | 104M | 120M | 120M |
| Intangibles | 274K | 4.7M | 4.3M | 23M | 20M | 17M | 17M |
| Retained Earnings | -23M | -20M | -17M | -29M | -35M | -102M | -102M |
| Working Capital | 182M | 399M | 405M | 336M | 329M | 314M | 314M |
| Current Assets | 209M | 432M | 454M | 392M | 396M | 392M | 392M |
| Current Liabilities | 27M | 33M | 49M | 56M | 68M | 78M | 78M |
| Per Share Data | |||||||
| EPS | 0.03 | 0.02 | 0.02 | -0.09 | -0.05 | -0.52 | -0.52 |
| Owner EPS | 0.14 | -0.02 | -0.24 | -0.17 | -0.07 | -0.29 | -0.29 |
| Book Value | -0.17 | 3.03 | 3.30 | 2.91 | 3.29 | 2.67 | 2.67 |
| Cash Flow/Share | 0.16 | 0.03 | -0.09 | 0.04 | 0.21 | -0.04 | -0.46 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 96.5M | 133.7M | 128.8M | 135.0M | 120.4M | 128.0M | 128.0M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | 485.5 | N/A | N/A | N/A | -8.8 |
| P/FCF | N/A | N/A | N/A | N/A | 35.2 | N/A | N/A |
| EV/EBIT | N/A | 198.9 | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 5.4 | 2.9 | 3.2 | 1.9 | 1.9 | 1.7 |
| Price/Sales | N/A | 23.5 | 9.9 | 6.0 | 3.8 | 2.7 | 2.9 |
| FCF Yield | N/A | 0.0% | -1.8% | 0.0% | 2.8% | -1.3% | -1.5% |
| Market Cap | N/A | 2.2B | 1.3B | 1.3B | 769M | 653M | 587M |
| Avg. Price | N/A | 22.21 | 12.56 | 8.52 | 6.38 | 4.23 | 4.59 |
| Year-End Price | N/A | 16.14 | 9.71 | 9.45 | 6.39 | 5.10 | 4.59 |
Cytek Biosciences, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 57.5%. Total shareholder yield (buybacks) is 13.8%. At current prices, the estimated annualized return to fair value is +47.6%.
Cytek Biosciences, Inc. (CTKB) has a 5-year average return on invested capital (ROIC) of -3.8%. This is below average and may indicate limited pricing power.
Cytek Biosciences, Inc. (CTKB) has a market capitalization of $587M. It is classified as a small-cap stock.
Cytek Biosciences, Inc. (CTKB) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 13.76%.
Cytek Biosciences, Inc. (CTKB) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
Cytek Biosciences, Inc. (CTKB) reported annual revenue of $201 million in its most recent fiscal year, based on SEC EDGAR filings.
Cytek Biosciences, Inc. (CTKB) has a net profit margin of -33.0%. The company is currently unprofitable.
Cytek Biosciences, Inc. (CTKB) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cytek Biosciences, Inc. (CTKB) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Cytek Biosciences, Inc. (CTKB) reported earnings per share (EPS) of $-0.52 in its most recent fiscal year.
Cytek Biosciences, Inc. (CTKB) has a return on equity (ROE) of -18.0%. A negative ROE may indicate losses or negative equity.
Cytek Biosciences, Inc. (CTKB) has a 5-year average gross margin of 57.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Cytek Biosciences, Inc. (CTKB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cytek Biosciences, Inc. (CTKB) has a book value per share of $2.67, based on its most recent annual SEC filing.